Click here to return to main plasmids page | ||||||
Papillomaviruses | Paper Name | Reference | Lab Name | Distribute? | Resistance | Notes |
BPV1 | [1] | pXL∫ | kan | Bicistronic, too large to self-package* | ||
| ||||||
BPV3 | unpublished | #2903 | yes, contact Martin Müller | amp | Bicistronic. Titer of BPV3 is very poor | |
| ||||||
BPV8 | unpublished | #2762 | yes, contact Martin Müller | amp | Bicistronic codon-modified L1/L2 expression plasmid | |
| ||||||
CRPV | [2] | p¢LLw | amp | Bicistronic, too large to self-package* | ||
|
| |||||
HPV1 | unpublished | p1LLw | not yet | amp | HPV1 gives poor L1 yield and HPV1 pseudovirus is poorly infectious | |
| ||||||
HPV2 | unpublished | p2LLw | yes | amp | This plasmid produces good yields of HPV2 prototype L1/L2 particles that have essentially no detectable infectivity on any tested cell line. | |
pRäLw | This variant (EF362755) HPV2 L1 produces pseudoviruses with detectable (but still extremely poor) infectious titer. Harvest 72h post-transfection | |||||
[3] | pä∫ | HPV2 L2 expression plasmid | ||||
HPV3 | [5] | Faust et al | amp | Bicistronic codon-modified L1/L2 expression plasmid. Pseudovirions are poorly infectious | ||
HPV5 | [6] | p5LLw | amp | Bicistronic, too large to self-package*. HPV5 has high particle to infectivity ratio on many cell types | ||
HPV6 | [7] | p6LLw2 | amp | † orignal "p6sheLL" had an unexpected duplication in the backbone due to a cloning error. The duplication was repaired in p6sheLLr. p6sheLL and p6sheLLr give essentially identical titer yields for HPV6 pseudovirus production. | ||
| ||||||
HPV11 | [8] | p11Lw | kan | Titer of HPV11 pseudovirus is very poor. Requires Müller MTA. | ||
| [9] | p11∫w | kan | |||
HPV15 | [5] | Faust et al | amp | Bicistronic codon-modified L1/L2 expression plasmid. Pseudovirions are poorly infectious | ||
HPV16 | p16LLw | amp | Replaces pXuLL. Bicistronic, too large to self-package*. Requires Müller MTA. | |||
phüL∫, frankenvirus | zeo | Synthetic HPV capable of self-packaging. Suitable for infectious amplification in 293TT cells. This plasmid is prone to collapse* | ||||
HPV18 | p18LLw | amp | Bicistronic, too large to self-package* | |||
HPV27 | Senger et al | [3] | ||||
HPV31 | p31LLw | amp | Bicistronic, too large to self-package*. Requires Kanda MTA. | |||
HPV32 | [5] | Faust et al | amp | Bicistronic codon-modified L1/L2 expression plasmid | ||
HPV33 | [5] | Faust et al | amp | Bicistronic codon-modified L1/L2 expression plasmid | ||
HPV35 | [15] | 5psh35F | amp | HPV35 L1 and L2 genes codon optimised for mammalian expression. Requires HPA UK MTA | ||
| ||||||
HPV38 | [16] | Faust et al | ||||
| ||||||
HPV39 | [15] | 39pshC | amp | HPV35 L1 and L2 genes codon optimised for mammalian expression. Requires HPA UK MTA (Simon Beddows) | ||
| ||||||
HPV45 | p45LLw | amp | Bicistronic, too large to self-package* | |||
| ||||||
HPV52 | [17] | p52LLw | amp | Bicistronic, too large to self-package*. Poor titer yield. Requires Kanda MTA. | ||
| ||||||
HPV56 | #3123 | unpublished | #3123 | yes, contact Martin Müller | amp | Bicistronic codon-modified L1/L2 expression plasmid |
| ||||||
HPV57 | Senger et al | [3] | Senger et al | |||
| ||||||
HPV58 | [14] | p58LLw | amp | Bicistronic, too large to self-package*. Requires Kanda MTA. | ||
|
| |||||
HPV59 | [15] | 59pshB | yes, contact Simon Beddows | amp | HPV35 L1 and L2 genes codon optimised for mammalian expression. Requires HPA UK MTA | |
|
| |||||
HPV68 | #2687 | unpublished | #2687 | yes, contact Martin Müller | amp | Bicistronic codon-modified L1/L2 expression plasmid |
HPV68 | [5] | Faust et al | amp | Bicistronic codon-modified L1/L2 expression plasmid | ||
HPV73 | #3122 | unpublished | #3122 | yes, contact Martin Müller | amp | Bicistronic codon-modified L1/L2 expression plasmid |
HPV76 | [5] | Faust et al | amp | Bicistronic codon-modified L1/L2 expression plasmid | ||
HPVs 6, 8, 11, 18, 26, 31, 33, 34, 35, 38, 29, 40, 42, 43, 44, 51, 52, 53, 56, 59, 66, 68, 70, 73 | [18] | kan | Roden and Kirnbauer labs | |||
|
| |||||
MusPV1 | [19] | pMuLLw | amp | Mammalian expression plasmid with codon modified L1 and L2 genes of Mus musculus papillomavirus type 1* | ||
| [20-22] | pMusPV | zeo | Synthetic Mus musculus papillomavirus type 1 clone | ||
|
| |||||
Polyomaviruses |
| |||||
BKV-I | [23] | Nakanishi et al | VP1/2/3 packaging plasmid for BKV serogroup I (isolate KOM5) reporter vectors | |||
| [24] | pIaw | yes | zeo | Codon modified BKV genotype Ia VP1 expression plasmid | |
|
| |||||
BKV-IV | [25] | pwB | yes | zeo | VP1 based on BKV serogroup IV isolate A-66H [26] | |
| [25] | pwB2b | zeo | BKV-IV VP1/VP2 dual expression plasmid | ||
| [25] | pwB3b | zeo | BKV-IV VP1/VP3 dual expression plasmid | ||
[25] | ph2b | zeo | BKV-IV VP2 expression plasmid | |||
[25] | ph3b | zeo | BKV-IV VP3 expression plasmid | |||
BKV variants | [24] | various | Yes | zeo | Codon modified VP1 ORFs from various BKV genotypes | |
HPyV6 | [27] | pe1D | zeo | Reference clone of human polyomavirus 6 | ||
| [27] | pe1VP1 | zeo | Human polyomavirus 6 VP1 expression construct | ||
HPyV7 | [27] | pe2S | zeo | Reference clone of human polyomavirus 7 | ||
| [27] | pe2VP1 | zeo | Human polyomavirus 7 VP1 expression construct | ||
HPyV10 | p10ww | yes | zeo | Reference clone of human polyomavirus 10 (MWPyV) | ||
| Unpublished | pVP1Xw | not yet | zeo | HPyV10 VP1 mammalian expression (codon modified) | |
| Unpublished | pVP2Xh | not yet | zeo | HPyV10 VP2 mammalian expression (codon modified) | |
| Unpublished | pVP3Xh | not yet | zeo | HPyV10 VP3 mammalian expression (codon modified) | |
| Unpublished | pVP1Xm | not yet | zeo | HPyV10 VP1 fused to MBP (bacterial expression) | |
JCV | [36] | p2Aw | not yet | zeo | Codon-modified JCV-2A (wt) VP1 expression plasmid | |
[36] | p3Brw | not yet | zeo | Codon-modified JCV-3B (wt) VP1 expression plasmid | ||
| [30] | p1Aw | zeo | Codon-modified JCV-Mad1 (genotype 1A) VP1 expression plasmid | ||
| [36] | p5053w | not yet | zeo | Inferred wt VP1 sequence of PML patients 5053, 5147, 5228 | |
| [36] | p5228m | not yet | zeo | PML-mutant VP1 sequence from CSF of PML patient 5147, 5228 | |
| [36] | ph2j | not yet | zeo | Codon-modified JCV consensus VP2 expression plasmid | |
| [36] | ph3j | not yet | zeo | Codon-modified JCV consensus VP3 expression plasmid | |
MCV | [27] | pMCV-L | kan | Wild-type MCV from healthy skin | ||
| [27] | p17A | yes | zeo | MCV w.t. reference clone. Replicates a bit better than R71a [31] | |
| unpublished | p16A | yes | zeo | MCV–R17a chimera with NCRR of Asian isolate MCV-16b | |
| [32] | pwM | zeo | Merkel cell polyomavirus (MCV) VP1 expression construct | ||
| [32] | ph2m | zeo | MCV VP2 expression construct | ||
| [33] | pwM2m | yes | zeo | MCV VP1/VP2 dual expression (VP2 expression relatively weak) | |
| [34] | pMmw | yes | amp | MCV VP1/VP2 expression, too big to self-package* | |
| [34] | P2mw | yes | amp or blast | MCV VP2, CMV promoter, non-replicating. Too big to package | |
| [34] | pCM | yes | amp | MCV VP1 expression, CMV promoter. Too big to package | |
|
| |||||
MPyV | [32] | pwP | zeo | Mouse polyomavirus (MPyV) VP1 expression construct | ||
| [32] | ph2p | zeo | MPyV VP2 expression construct | ||
| [32] | ph3p | zeo | MPyV VP3 expression construct | ||
BoPyV | [35] | pFF-S5BPyV1clonex | zeo | Re-ligatable bovine polyomavirus 1 isolate 1S22 | ||
[35] | pFF-S11BPyV2aclone2 | zeo | Re-ligatable bovine polyomavirus 2a isolate 2aS22 | |||
[35] | pFF-S5BPyV2bcloneq | zeo | Re-ligatable bovine polyomavirus 2b isolate 2bS24 | |||
[35] | pFF-BPyV3clone1 | zeo | Re-ligatable bovine polyomavirus 3 isolate 3S22 | |||
[35] | pFF-BPyV3clone2 | zeo | Re-ligatable bovine polyomavirus 3 isolate 3S23 | |||
Adomaviruses | ||||||
Marbled eel | unpublished | pAdOM-E | yes | zeo | Marbled eel adomavirus AclI-EcoRI fragment (early region) | |
unpublished | pAdOM-L | yes | zeo | Marbled eel adomavirus AclI-EcoRI fragment (late region) | ||
unpublished | yes | zeo | Marbled eel adomavirus late ORF expression (EF1alpha promoter) | |||
unpublished | yes | zeo | Marbled eel adomavirus late ORF expression (EF1alpha promoter) | |||
unpublished | yes | zeo | Marbled eel adomavirus late ORF expression (EF1alpha promoter) | |||
unpublished | yes | zeo | Marbled eel adomavirus late ORF expression (EF1alpha promoter) | |||
unpublished | yes | zeo | Marbled eel adomavirus late ORF expression (EF1alpha promoter) | |||
unpublished | yes | zeo | Marbled eel adomavirus late ORF expression (EF1alpha promoter) | |||
unpublished | yes | zeo | Marbled eel adomavirus late ORF expression (EF1alpha promoter) | |||
*Plasmids >10kb can be unstable in E. coli. | ||||||
Growing bacterial starter cultures at 30ºC and/or using Invitrogen STBL2 or Stratagene XL10-Gold bacteria may decrease the risk of plasmid collapse. |
1. Buck, C.B., D.V. Pastrana, D.R. Lowy, and J.T. Schiller, Efficient intracellular assembly of papillomaviral vectors.J Virol, 2004. 78(2): p. 751-7.
http://www.ncbi.nlm.nih.gov/pubmed/14694107
2. Roberts, J.N., C.B. Buck, C.D. Thompson, R. Kines, M. Bernardo, P.L. Choyke, D.R. Lowy, and J.T. Schiller, Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan.Nat Med, 2007. 13(7): p. 857-61.
http://www.ncbi.nlm.nih.gov/pubmed/17603495
3. Senger, T., L. Schadlich, S. Textor, C. Klein, K.M. Michael, C.B. Buck, and L. Gissmann, Virus-like particles and capsomeres are potent vaccines against cutaneous alpha HPVs.Vaccine, 2010. 28(6): p. 1583-93.
4. Wang, W., C. Wang, S. Xu, C. Chen, X. Tong, Y. Liang, X. Dong, Y. Lei, X. Zheng, J. Yu, and J. Wang, Detection of HPV-2 and identification of novel mutations by whole genome sequencing from biopsies of two patients with multiple cutaneous horns.J Clin Virol, 2007.39(1): p. 34-42.
http://www.ncbi.nlm.nih.gov/pubmed/17368088
5. Faust, H., K. Andersson, O. Forslund, and J. Dillner, Pseudovirion-binding and neutralizing antibodies to cutaneous human papillomaviruses (HPV) correlated with the presence of HPV DNA in skin.J Gen Virol, 2013. 94(Pt 5): p. 1096-103.
https://www.ncbi.nlm.nih.gov/pubmed/23343629
6. Buck, C.B., C.D. Thompson, J.N. Roberts, M. Muller, D.R. Lowy, and J.T. Schiller, Carrageenan is a potent inhibitor of papillomavirus infection.PLoS Pathog, 2006. 2(7): p. e69.
7. Pastrana, D.V., R. Gambhira, C.B. Buck, Y.Y. Pang, C.D. Thompson, T.D. Culp, N.D. Christensen, D.R. Lowy, J.T. Schiller, and R.B. Roden, Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2.Virology, 2005. 337(2): p. 365-72.
8. Mossadegh, N., L. Gissmann, M. Muller, H. Zentgraf, A. Alonso, and P. Tomakidi, Codon optimization of the human papillomavirus 11 (HPV 11) L1 gene leads to increased gene expression and formation of virus-like particles in mammalian epithelial cells.Virology, 2004. 326(1): p. 57-66.
9. Kieback, E. and M. Muller, Factors influencing subcellular localization of the human papillomavirus L2 minor structural protein.Virology, 2006. 345(1): p. 199-208.
10. Leder, C., J.A. Kleinschmidt, C. Wiethe, and M. Muller, Enhancement of capsid gene expression: preparing the human papillomavirus type 16 major structural gene L1 for DNA vaccination purposes.J Virol, 2001. 75(19): p. 9201-9.
11. Buck, C.B. and C.D. Thompson, Production of papillomavirus-based gene transfer vectors.Curr Protoc Cell Biol, 2007. Chapter 26: p. Unit 26.1.
http://www.ncbi.nlm.nih.gov/pubmed/18228512
12. Buck, C.B., N. Cheng, C.D. Thompson, D.R. Lowy, A.C. Steven, J.T. Schiller, and B.L. Trus, Arrangement of L2 within the papillomavirus capsid.J Virol, 2008. 82(11): p. 5190-7.
13. Pastrana, D.V., C.B. Buck, Y.Y. Pang, C.D. Thompson, P.E. Castle, P.C. FitzGerald, S. Kruger Kjaer, D.R. Lowy, and J.T. Schiller, Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.Virology, 2004. 321(2): p. 205-16.
http://www.ncbi.nlm.nih.gov/pubmed/15051381
14. Kondo, K., Y. Ishii, H. Ochi, T. Matsumoto, H. Yoshikawa, and T. Kanda, Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.Virology, 2007. 358(2): p. 266-72.
15. Draper, E., S.L. Bissett, R. Howell-Jones, D. Edwards, G. Munslow, K. Soldan, and S. Beddows, Neutralization of Non-Vaccine Human Papillomavirus Pseudoviruses from the A7 and A9 Species Groups by Bivalent HPV Vaccine Sera.Vaccine, 2011. 29: p. 8585-90.
https://www.ncbi.nlm.nih.gov/pubmed/21939712
16. Faust, H., P. Knekt, O. Forslund, and J. Dillner, Validation of multiplexed human papillomavirus serology using pseudovirions bound to heparin coated beads.J Gen Virol, 2010.
17. Kondo, K., H. Ochi, T. Matsumoto, H. Yoshikawa, and T. Kanda, Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes.J Med Virol, 2008. 80(5): p. 841-6.
18. Kwak, K., R. Jiang, J.W. Wang, S. Jagu, R. Kirnbauer, and R.B. Roden, Impact of inhibitors and L2 antibodies upon the infectivity of diverse alpha and beta human papillomavirus types.PLoS One, 2014. 9(5): p. e97232.
http://www.ncbi.nlm.nih.gov/pubmed/24816794
19. Handisurya, A., P.M. Day, C.D. Thompson, C.B. Buck, K. Kwak, R.B. Roden, D.R. Lowy, and J.T. Schiller, Murine skin and vaginal mucosa are similarly susceptible to infection by pseudovirions of different papillomavirus classifications and species.Virology, 2012. 433(2): p. 385-94.
http://www.ncbi.nlm.nih.gov/pubmed/22985477
20. Joh, J., A.B. Jenson, W. King, M. Proctor, A. Ingle, J.P. Sundberg, and S.J. Ghim, Genomic analysis of the first laboratory-mouse papillomavirus.The Journal of general virology, 2011. 92(Pt 3): p. 692-8.
http://www.ncbi.nlm.nih.gov/pubmed/21084500
21. Ingle, A., S. Ghim, J. Joh, I. Chepkoech, A. Bennett Jenson, and J.P. Sundberg, Novel laboratory mouse papillomavirus (MusPV) infection.Vet Pathol, 2011. 48(2): p. 500-5.
http://www.ncbi.nlm.nih.gov/pubmed/20685915
22. Handisurya, A., P.M. Day, C.D. Thompson, C.B. Buck, Y.Y. Pang, D.R. Lowy, and J.T. Schiller, Characterization of Mus musculus Papillomavirus 1 (MusPV1) Infection in Situ Reveals an Unusual Pattern of Late Gene Expression and Capsid Protein Localization.J Virol, 2013. 87(24): p. 13214-25.
23. Nakanishi, A., B. Chapellier, N. Maekawa, M. Hiramoto, T. Kuge, R.U. Takahashi, H. Handa, and T. Imai, SV40 vectors carrying minimal sequence of viral origin with exchangeable capsids.Virology, 2008. 379(1): p. 110-7.
24. Pastrana, D.V., U. Ray, T.G. Magaldi, R.M. Schowalter, N. Çuburu, and C.B. Buck, BK Polyomavirus Genotypes Represent Distinct Serotypes with Distinct Entry Tropisms.J Virol, 2013. 87(18): p. 10105-13.
http://www.ncbi.nlm.nih.gov/pubmed/23843634
25. Schowalter, R.M., D.V. Pastrana, and C.B. Buck, Glycosaminoglycans and sialylated glycans sequentially facilitate merkel cell polyomavirus infectious entry.PLoS Pathog, 2011. 7(7): p. e1002161.
http://www.ncbi.nlm.nih.gov/pubmed/21829355
26. Zhong, S., P.S. Randhawa, H. Ikegaya, Q. Chen, H.Y. Zheng, M. Suzuki, T. Takeuchi, A. Shibuya, T. Kitamura, and Y. Yogo, Distribution patterns of BK polyomavirus (BKV) subtypes and subgroups in American, European and Asian populations suggest co-migration of BKV and the human race.J Gen Virol, 2009. 90(Pt 1): p. 144-52.
27. Schowalter, R.M., D.V. Pastrana, K.A. Pumphrey, A.L. Moyer, and C.B. Buck, Merkel Cell Polyomavirus and Two Previously Unknown Polyomaviruses Are Chronically Shed From Human Skin.Cell Host Microbe, 2010. 7(6): p. 509-15.
http://www.ncbi.nlm.nih.gov/pubmed/20542254
28. Buck, C.B., G.Q. Phan, M.T. Raiji, P.M. Murphy, D.H. McDermott, and A.A. McBride, Complete genome sequence of a tenth human polyomavirus.Journal of virology, 2012. 86(19): p. 10887.
http://www.ncbi.nlm.nih.gov/pubmed/22966183
29. Siebrasse, E.A., A. Reyes, E.S. Lim, G. Zhao, R.S. Mkakosya, M.J. Manary, J.I. Gordon, and D. Wang, Identification of MW polyomavirus, a novel polyomavirus in human stool.J Virol, 2012. 86(19): p. 10321-6.
http://www.ncbi.nlm.nih.gov/pubmed/22740408
30. Maginnis, M.S., L.J. Stroh, G.V. Gee, B.A. O'Hara, A. Derdowski, T. Stehle, and W.J. Atwood, Progressive multifocal leukoencephalopathy-associated mutations in the JC polyomavirus capsid disrupt lactoseries tetrasaccharide c binding.MBio, 2013. 4(3): p. e00247-13.
http://www.ncbi.nlm.nih.gov/pubmed/23760462
31. Neumann, F., S. Borchert, C. Schmidt, R. Reimer, H. Hohenberg, N. Fischer, and A. Grundhoff, Replication, Gene Expression and Particle Production by a Consensus Merkel Cell Polyomavirus (MCPyV) Genome.PLoS One, 2011. 6(12): p. e29112.
http://www.ncbi.nlm.nih.gov/pubmed/22216177
32. Tolstov, Y.L., D.V. Pastrana, H. Feng, J.C. Becker, F.J. Jenkins, S. Moschos, Y. Chang, C.B. Buck, and P.S. Moore, Human Merkel cell polyomavirus infection II. MCV is a common human infection that can be detected by conformational capsid epitope immunoassays.Int J Cancer, 2009.125(6): p. 1250-6.
33. Pastrana, D.V., K.A. Pumphrey, N. Çuburu, R.M. Schowalter, and C.B. Buck, Characterization of monoclonal antibodies specific for the Merkel cell polyomavirus capsid.Virology, 2010. 405(1): p. 20-5.
34. Schowalter, R.M. and C.B. Buck, The Merkel cell polyomavirus minor capsid protein.PLoS Pathog, 2013. 9(8): p. e1003558.
http://www.ncbi.nlm.nih.gov/pubmed/23990782
35. Peretti, A., P.C. FitzGerald, V. Bliskovsky, C.B. Buck, and D.V. Pastrana, Hamburger polyomaviruses.J Gen Virol, 2015.
http://www.ncbi.nlm.nih.gov/pubmed/25568187
36. Ray U, Cinque P, Gerevini S, Longo V, Schippling S, Martin R, Buck CB, Pastrana DV: JC Polyomavirus Mutants Escape Antibody-Mediated Neutralization. Science Translational Medicine 2015, 7:306ra151.
https://www.ncbi.nlm.nih.gov/pubmed/29091757